Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03225027
Other study ID # CHRD0814
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 15, 2016
Est. completion date May 27, 2019

Study information

Verified date July 2019
Source Centre Hospitalier René Dubos
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the present study is to evaluate the effect of emotional prosody on the perception of emotional discourse in the schizophrenic spectrum. The investigators hypothesize that participant may use emotional prosody as an emotional cue to understand the emotional content of discourse.


Description:

The integration of ortholinguistic and paralinguistic functions in language, particularly of the emotional prosody, is necessary to interact adaptively with others. People in the schizophrenic spectrum have social difficulties. Is emotional prosody comprehension altered in these people? According to Edwards et al. (2002), there is methodological issues concerning the tasks used to answer this question. Investigators built an emotional judgment task more adapted to study the perception of emotional prosody in the schizophrenic spectrum than the classical paradigm designed to evaluate participants with cerebral injury. The investigators have elaborated a material that consists of 140 short sentences (7±2 words) with a simple syntactic structure. The verbal content expressed positive, neutral or negative emotions. These sentences were announced by four professional actors (two female) with an emotional prosody content congruent or inconsistent with the verbal content. Participants will have to evaluate the emotional intensity of the recordings on a five points Likert scale, from strongly negative to strongly positive. Psychotic experiences of all participants will be evaluated too.


Recruitment information / eligibility

Status Completed
Enrollment 59
Est. completion date May 27, 2019
Est. primary completion date May 27, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Having a diagnosis of schizophrenia and being in a stable phase of the disease

- Having between 18 to 60 years old

- Speak french or using french at school

- Accepting not to use psychoactive substances during the preceding 48h

- Being affiliated to the French social security

- Providing their written informed consent

Non-inclusion Criteria:

- Having not audio deficits, nor visual uncorrected deficits

- Having not suffering from depressive symptoms during the last 6 months

Exclusion Criteria:

- Having no neurological, nor psychiatric disease except schizophrenia for the patients groups.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Emotional judgment task
Participants had to indicate on a computer the emotional intensity of audio recordings.
Post-experimental questionnaire
Participants will be invited to give us the cognitive strategy used to resolve the emotional judgment task.
Recognition task
Participants will be invited to indicate which recordings they had heard during the emotional judgment task to verify that they have paid attention to the emotional task.
Detection task
Participants indicate every time they heard a given sound in order to verify their audition level.
Other:
CAPE-42
This questionnaire allows evaluating the nature of psychotic experiences.
Diagnostic Test:
Trait Emotional Intelligence Questionnaire
To evaluate their emotional intelligence.
Positive And Negative Syndrome Scale
Evaluating the clinical status of patients with schizophrenia.
Other:
Mini International Neuropsychiatric Interview
Evaluating the exclusion criteria in healthy participants.

Locations

Country Name City State
France HDJ François Villon Cergy-Pontoise

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier René Dubos

Country where clinical trial is conducted

France, 

References & Publications (3)

Beaucousin V, Lacheret A, Turbelin MR, Morel M, Mazoyer B, Tzourio-Mazoyer N. FMRI study of emotional speech comprehension. Cereb Cortex. 2007 Feb;17(2):339-52. Epub 2006 Mar 8. — View Citation

Brazo P, Beaucousin V, Lecardeur L, Razafimandimby A, Dollfus S. Social cognition in schizophrenic patients: the effect of semantic content and emotional prosody in the comprehension of emotional discourse. Front Psychiatry. 2014 Sep 10;5:120. doi: 10.338 — View Citation

Edwards J, Jackson HJ, Pattison PE. Emotion recognition via facial expression and affective prosody in schizophrenia: a methodological review. Clin Psychol Rev. 2002 Jul;22(6):789-832. Review. Erratum in: Clin Psychol Rev. 2002 Nov;22(8):1267-85. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Behavioural measures (response rate and time) Participants will have to judge the emotional intensity of audio recordings. In this task, the participant is asked to judge the emotional intensity of audio recordings of men and women (2 actors + 2 actresses): he / she must press a button as quickly as possible to indicate whether the Audio recordings presented via small speakers are very negative, negative, non-emotional, positive or very positive (5 possible choices).
The response time variable may be added as a co-variable in order to avoid perceptive-motor disorders (medication-related and / or general motor slowdown) that may influence the results of time-of- answers.
During the experiment
Secondary Symptomatic impact Evaluate the nature of the psychotic experiments (CAPE-42 test). During the experiment
Secondary Evaluate the cognitive functioning Neuropsychological tests will allow evaluating the cognitive profile of the participants that can impact their behaviour during the experiment. During the experiment